•$BridgeBio Pharma (BBIO.US)$+5%(to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference)
•$BlueCity (BLCT.US)$+3.5% (trading halted June 9 and June 10; BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy to be discussed at an FDA Advisory Committee Meeting)
•$Martin Midstream (MMLP.US)$-4.9% (files for $250 mln mixed securities shelf offering; also files for 6,114,532 common unit offering by selling unitholders)
•$Viewray (VRAY.US)$-4.7% (announced that the VA Ann Arbor Healthcare System (VAAAHS) has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services)